oral wegovy

The tag 'oral wegovy' covers discussions about Novo Nordisk's oral formulation of Wegovy, including its regulatory progress, prescription momentum, and upcoming Medicare coverage for eligible obesity patients starting July 1, 2026. Content also addresses a disclosed clinical-trial data breach that impacts investor confidence, as well as broader themes of GLP-1 competition, pricing pressure, and cybersecurity risks in the pharmaceutical sector. The tag is relevant for investors and healthcare professionals tracking the operational and financial trajectory of Novo Nordisk's oral obesity treatment.